Limits...
Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases.

Gopal S, Xu H, Bossie C, Burón JA, Fu DJ, Savitz A, Nuamah I, Hough D - Int. J. Clin. Pract. (2014)

Bottom Line: Spontaneously reported TD adverse events (AEs) were also summarised.Pali ER (five studies, N = 2054), were: spontaneously reported AE, 0.18% (PP) vs. 0.10% (Pali ER); probable TD, 0.12% (PP) vs. 0.19% (Pali ER) and persistent TD, 0.12% (PP) vs. 0.05% (Pali ER).Mean exposure: PP, 279.6 days; Pali ER, 187.2 days.

View Article: PubMed Central - PubMed

Affiliation: Janssen Research & Development, LLC, Titusville, NJ, USA.

No MeSH data available.


Related in: MedlinePlus

Incidence of dyskinesia over time. Dyskinesia defined as abnormal involuntary movement scale total score of at least 3.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4265240&req=5

fig01: Incidence of dyskinesia over time. Dyskinesia defined as abnormal involuntary movement scale total score of at least 3.

Mentions: Incidence of all dyskinesia (total AIMS score ≥ 3 at any single visit) was highest within the first treatment month (Table4) for both PP (13.1%) and Pali ER (11.7%) treated groups and steadily decreased over time (Figure1).


Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases.

Gopal S, Xu H, Bossie C, Burón JA, Fu DJ, Savitz A, Nuamah I, Hough D - Int. J. Clin. Pract. (2014)

Incidence of dyskinesia over time. Dyskinesia defined as abnormal involuntary movement scale total score of at least 3.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4265240&req=5

fig01: Incidence of dyskinesia over time. Dyskinesia defined as abnormal involuntary movement scale total score of at least 3.
Mentions: Incidence of all dyskinesia (total AIMS score ≥ 3 at any single visit) was highest within the first treatment month (Table4) for both PP (13.1%) and Pali ER (11.7%) treated groups and steadily decreased over time (Figure1).

Bottom Line: Spontaneously reported TD adverse events (AEs) were also summarised.Pali ER (five studies, N = 2054), were: spontaneously reported AE, 0.18% (PP) vs. 0.10% (Pali ER); probable TD, 0.12% (PP) vs. 0.19% (Pali ER) and persistent TD, 0.12% (PP) vs. 0.05% (Pali ER).Mean exposure: PP, 279.6 days; Pali ER, 187.2 days.

View Article: PubMed Central - PubMed

Affiliation: Janssen Research & Development, LLC, Titusville, NJ, USA.

No MeSH data available.


Related in: MedlinePlus